DOCSLIB.ORG

PGENETICS-D-11-00413 Title: Integrating

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PGENETICS-D-11-00413 Title: Integrating Editorial Manager(tm) for PLoS Genetics Manuscript Draft Manuscript Number: PGENETICS-D-11-00413 Title: Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets Short Title: Integrative association analysis of gene sets Article Type: Research Article Section/Category: Natural Variation Keywords: gene set analysis; eQTL; integrative genomics Corresponding Author: Sayan Mukherjee Corresponding Author's Institution: Duke University First Author: Qing Xiong Order of Authors: Qing Xiong;Nicola Ancona;Elizabeth Hauser;Sayan Mukherjee;Terrence Furey Abstract: Background: Single variant or single gene analyses generally account for only a small proportion of the phenotypic variation in complex traits. Alternatively, gene set or pathway association analyses are playing an increasingly important role in uncovering genetic architectures of complex traits through the identification of systematic genetic interactions. Two dominant paradigms for gene set analyses are association analyses based on SNP genotypes and those based on gene expression profiles. However, gene-disease association can manifest in many ways such as alterations of gene expression, genotype and copy number, thus an integrative approach combining multiple forms of evidence can more accurately and comprehensively capture pathway associations. Methodology: We have developed a single statistical framework, Gene Set Association Analysis (GSAA), that simultaneously measures genome-wide patterns of genetic variation and gene expression variation to identify sets of genes enriched for differential expression and/or trait-associated genetic markers. Simulation studies illustrate that joint analyses of genomic data increase the power to detect real associations when compared to gene set methods that use only one genomic data type. Significance/Findings: The analyses of two human disease, glioblastoma and Crohn's disease, detected abnormalities in previously identified disease-associated pathways, such as pathways related to the PI3K signaling, DNA damage response, and activation of NF-κB. In addition, GSAA revealed novel pathway associations, for example differential genetic and expression characteristics in genes from the ABC transporter family in glioblastoma and from the HLA system in Crohn's disease. These demonstrate that GSAA can help uncover biological pathways underlying human diseases and complex traits. Software is freely available at http://gsaa.genome.duke.edu. Suggested Reviewers: Eleazar Eskin UCLA [email protected] Eric Stone North Carolina State Unviersity [email protected] Emmanouil Dermitzakis Wellcome Trust Sanger Institute [email protected] Vamsi Mootha Harvard University [email protected] Opposed Reviewers: Cover Letter DUKE UNIVERSITY DEPARTMENT OF STATISTICAL SCIENCE D URHAM NC 27708-0251 - USA SAYAN MUKHERJEE ASSISTANT PROFESSOR OF STATISTICAL SCIENCE COMPUTER SCIENCE AND MATHEMATICS INVESTIGATOR INSTITUTE FOR GENOME Wednesday, February 23, 2011 SCIENCES & POLICY tel/fax: +1 919 684 4608/8594 [email protected] Dear Editor: We are submitting our manuscript entitled "Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets" for your review. Increasing amounts of diverse genome-wide data for complex traits and diseases are available and continue being rapidly generated, but our understanding of these data is not keeping pace. The primary goal of this study is to develop a more effective method to simultaneously leverage information from multiple genomic data, particularly genotype and expression data, to identify biological pathways underlying complex traits and diseases. We believe that this work represents a substantial advance in the joint analysis of genome-wide association data and genome-wide expression data in the context of complex traits and diseases and will be of broad interest to your readership. Two major approaches to uncover the genetic architecture of traits have been genome-wide association studies (GWAS), to examine correlations between individual genetic variants and trait variation, and gene expression-based studies, to examine correlations between gene expression and trait variation. Despite the enormous success of GWA studies, the identified single nucleotide polymorphisms (SNPs) explain only a small proportion of the phenotypic variation, and the predictive power of these SNPs remains low for many complex diseases. Gene set or pathway- based approaches have shown some success as an alternative to single locus analyses in an attempt to address the limited explanatory power of identified single variants. However, existing approaches have focused on pathway analyses of a single data type, especially genotype data or expression data, and didn’t offer a integrative solution at the pathway level that takes advantage of the complementary information available in different genome-wide data such as genotype and expression information. Our novel Gene Set Association Analysis (GSAA) method integrates multiple genomic data to better understand the biology of complex traits. GSAA simultaneously considers multiple data types employing a pathway-based approach that has been repeatedly shown to be more robust than single gene analyses and offers an increased interpretability of results. Importantly, GSAA does not require matched samples, meaning expression and genotype data need not be from the same samples. Thus, combinations of existing GWAS and expression data generated from different studies can be readily employed. We conducted a comprehensive simulation study and show that GSAA has greater power to detect association signals than other methods. We employed GSAA in an analysis ofglioblastoma and Crohn’s disease data to demonstrate its utility in analysis and interpretation. Our results show that GSAA can robustly detect signals found in either data type and better highlights key pathways that show variation at the genotype level as well as the expression level. While we concentrate on gene expression and genotype data, GSAA is easily extensible to accommodate additional data types such as DNA copy number or DNA methylation data. The general framework of GSAA will also allow the incorporation of higher resolution genome sequence data as it becomes available for greater numbers of samples in the future. In short, we believe our work described in this manuscript provides a critical methodological advance in genome analyses of complex traits and clearly illustrates its utility on data from previous studies of human disease. We believe that GSAA will greatly complement current GWAS analyses and offers an important alternative way in which to comprehensively understand the genetic underpinnings underlying complex traits and diseases. We strongly believe this work will be of great interest to a broad audience and that your journal is the proper venue for its publication. PLoS Genetics has a number of excellent associate editors on its board. For this particular work, we believe that Vivian Cheung in particular has the most appropriate knowledge and background to accurately evaluate the merits of our submission. If Dr. Cheung is unable to act as the editor, we feel that Leonid Kruglyak and GoncaloAbecasis would also be well qualified. Please note that we submitted an earlier version of this paper to PLoS Genetics. Greg Gibson was the section editor. We addressed all of the reviewer comments from that submission. This new paper is very different from our previous submission, in part due to all of the changes addressing the reviewer comments. That review and our responses are included in Yours sincerely, Sayan Mukherjee, on behalf of the other authors 2 *Manuscript Click here to download Manuscript: gsaa_manuscript.pdf 1 Integrating genetic and gene expression evidence into genome-wide association 2 analysis of gene sets 3 Qing Xiong1, Nicola Ancona2, Elizabeth R. Hauser3, Sayan Mukherjee4,#,*, Terrence S. Furey1,#,* 4 1Department of Genetics, Department of Biology, Lineberger Comprehensive Cancer Center, and 5 Carolina Center for Genomics and Society, The University of North Carolina at Chapel Hill, Chapel Hill, 6 NC 27599, USA; 7 2Institute of Intelligent Systems for Automation National Research Council, Bari IT 70126, Italy; 8 3Center for Human Genetics and Section of Medical Genetics, Department of Medicine, Duke University, 9 Durham, NC 27710, USA; 10 4Departments of Statistical Science, Computer Science, and Mathematics, Institute for Genome Sciences 11 & Policy, Duke University, Durham, NC 27708, USA; 12 #These authors contributed equally to this work 13 *E-mail: [email protected] (SM), [email protected] (TSF) 14 1 15 Abstract 16 17 Single variant or single gene analyses generally account for only a small proportion of the phenotypic 18 variation in complex traits. Alternatively, gene set or pathway association analyses are playing an 19 increasingly important role in uncovering genetic architectures of complex traits through the identification 20 of systematic genetic interactions. Two dominant paradigms for gene set analyses are association analyses 21 based on SNP genotypes and those based on gene expression profiles. However, gene-disease association 22 can manifest in many ways such as alterations of gene expression, genotype and copy number, thus an 23 integrative approach combining multiple forms of evidence can more accurately and comprehensively 24 capture pathway associations. We have developed a single statistical framework, Gene Set
Load more

Recommended publications
  • Transcriptomic Characterization of Fibrolamellar Hepatocellular
    Transcriptomic characterization of fibrolamellar PNAS PLUS hepatocellular carcinoma Elana P. Simona, Catherine A. Freijeb, Benjamin A. Farbera,c, Gadi Lalazara, David G. Darcya,c, Joshua N. Honeymana,c, Rachel Chiaroni-Clarkea, Brian D. Dilld, Henrik Molinad, Umesh K. Bhanote, Michael P. La Quagliac, Brad R. Rosenbergb,f, and Sanford M. Simona,1 aLaboratory of Cellular Biophysics, The Rockefeller University, New York, NY 10065; bPresidential Fellows Laboratory, The Rockefeller University, New York, NY 10065; cDivision of Pediatric Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; dProteomics Resource Center, The Rockefeller University, New York, NY 10065; ePathology Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; and fJohn C. Whitehead Presidential Fellows Program, The Rockefeller University, New York, NY 10065 Edited by Susan S. Taylor, University of California, San Diego, La Jolla, CA, and approved September 22, 2015 (received for review December 29, 2014) Fibrolamellar hepatocellular carcinoma (FLHCC) tumors all carry a exon of DNAJB1 and all but the first exon of PRKACA. This deletion of ∼400 kb in chromosome 19, resulting in a fusion of the produced a chimeric RNA transcript and a translated chimeric genes for the heat shock protein, DNAJ (Hsp40) homolog, subfam- protein that retains the full catalytic activity of wild-type PKA. ily B, member 1, DNAJB1, and the catalytic subunit of protein ki- This chimeric protein was found in 15 of 15 FLHCC patients nase A, PRKACA. The resulting chimeric transcript produces a (21) in the absence of any other recurrent mutations in the DNA fusion protein that retains kinase activity.
    [Show full text]
  • Alters Enhancer Function in the Developing Telencephalon Meis1
    Downloaded from genome.cshlp.org on March 19, 2014 - Published by Cold Spring Harbor Laboratory Press Restless Legs Syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon Derek Spieler, Maria Kaffe, Franziska Knauf, et al. Genome Res. published online March 18, 2014 Access the most recent version at doi:10.1101/gr.166751.113 Supplemental http://genome.cshlp.org/content/suppl/2014/02/10/gr.166751.113.DC1.html Material P<P Published online March 18, 2014 in advance of the print journal. Open Access Freely available online through the Genome Research Open Access option. Creative This article, published in Genome Research, is available under a Creative Commons Commons License (Attribution-NonCommercial 3.0 Unported), as described at License http://creativecommons.org/licenses/by-nc/3.0/. Email Alerting Receive free email alerts when new articles cite this article - sign up in the box at the Service top right corner of the article or click here. Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication. To subscribe to Genome Research go to: http://genome.cshlp.org/subscriptions © 2014 Spieler et al.; Published by Cold Spring Harbor Laboratory Press Downloaded from genome.cshlp.org on March 19, 2014 - Published by Cold Spring Harbor Laboratory Press Research Restless Legs Syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon Derek Spieler,1,25 Maria Kaffe,1,2,25 Franziska Knauf,1,25 Jose´ Bessa,3 Juan J.
    [Show full text]
  • Overall Survival of Pancreatic Ductal Adenocarcinoma Is Doubled by Aldh7a1 Deletion in the KPC Mouse
    Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse Jae-Seon Lee1,2*, Ho Lee3*, Sang Myung Woo4, Hyonchol Jang1, Yoon Jeon1, Hee Yeon Kim1, Jaewhan Song2, Woo Jin Lee4, Eun Kyung Hong5, Sang-Jae Park4, Sung- Sik Han4§§ and Soo-Youl Kim1§ 1Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Republic of Korea. 2Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. 3Graduate School of Cancer Science and Policy, 4Department of Surgery, Center for Liver and Pancreatobiliary Cancer and 5Department of Pathology, National Cancer Center, Goyang, Republic of Korea. Correspondence §Corresponding author: [email protected] (S.-Y.K.) §§Co-corresponding author: [email protected] (S.-S.H.) *These authors contributed equally to this work 1 Abstract Rationale: The activity of aldehyde dehydrogenase 7A1 (ALDH7A1), an enzyme that catalyzes the lipid peroxidation of fatty aldehydes was found to be upregulated in pancreatic ductal adenocarcinoma (PDAC). ALDH7A1 knockdown significantly reduced tumor formation in PDAC. We raised a question how ALDH7A1 contributes to cancer progression. Methods: To answer the question, the role of ALDH7A1 in energy metabolism was investigated by knocking down and knockdown gene in mouse model, because the role of ALDH7A1 has been reported as a catabolic enzyme catalyzing fatty aldehyde from lipid peroxidation to fatty acid. Oxygen consumption rate (OCR), ATP production, mitochondrial membrane potential, proliferation assay and immunoblotting were performed. In in vivo study, two human PDAC cell lines were used for pre-clinical xenograft model as well as spontaneous PDAC model of KPC mice was also employed for anti-cancer therapeutic effect.
    [Show full text]
  • Update on the Aldehyde Dehydrogenase Gene (ALDH) Superfamily Brian Jackson,1 Chad Brocker,1 David C
    GENOME UPDATE Update on the aldehyde dehydrogenase gene (ALDH) superfamily Brian Jackson,1 Chad Brocker,1 David C. Thompson,2 William Black,1 Konstandinos Vasiliou,1 Daniel W. Nebert3 and Vasilis Vasiliou1* 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267, USA *Correspondence to: Tel: þ1 303 724 3520; Fax: þ1 303 724 7266; E-mail: [email protected] Date received (in revised form): 23rd March 2011 Abstract Members of the aldehyde dehydrogenase gene (ALDH) superfamily play an important role in the enzymic detoxifi- cation of endogenous and exogenous aldehydes and in the formation of molecules that are important in cellular processes, like retinoic acid, betaine and gamma-aminobutyric acid. ALDHs exhibit additional, non-enzymic func- tions, including the capacity to bind to some hormones and other small molecules and to diminish the effects of ultraviolet irradiation in the cornea. Mutations in ALDH genes leading to defective aldehyde metabolism are the molecular basis of several diseases, including gamma-hydroxybutyric aciduria, pyridoxine-dependent seizures, Sjo¨gren–Larsson syndrome and type II hyperprolinaemia. Interestingly, several ALDH enzymes appear to be markers for normal and cancer stem cells. The superfamily is evolutionarily ancient and is represented within Archaea, Eubacteria and Eukarya taxa. Recent improvements in DNA and protein sequencing have led to the identification of many new ALDH family members.
    [Show full text]
  • Mouse Aldehyde Dehydrogenase ALDH3B2 Is Localized to Lipid Droplets Via Two C-Terminal Tryptophan Residues and Title Lipid Modification
    Mouse aldehyde dehydrogenase ALDH3B2 is localized to lipid droplets via two C-terminal tryptophan residues and Title lipid modification Author(s) Kitamura, Takuya; Takagi, Shuyu; Naganuma, Tatsuro; Kihara, Akio Biochemical journal, 465, 79-87 Citation https://doi.org/10.1042/BJ20140624 Issue Date 2015-01-02 Doc URL http://hdl.handle.net/2115/60410 Rights The Version of Record (VoR) is available at www.biochemj.org Type article (author version) File Information manuscript.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Mouse aldehyde dehydrogenase ALDH3B2 is localized to lipid droplets via two C-terminal tryptophan residues and lipid modification Takuya Kitamura*, Shuyu Takagi*, Tatsuro Naganuma*, and Akio Kihara*1 *Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812, Japan 1To whom correspondence should be addressed: Akio Kihara Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences Hokkaido University Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812, Japan Tel.: +81-11-706-3754 Fax: +81-11-706-4900 E-mail: [email protected] Short title: Lipid droplet localization of ALDH3B2 Summary statement: The mouse aldehyde dehydrogenases ALDH3B2 and ALDH3B3 exhibit similar substrate specificity but distinct intracellular localization (ALDH3B2, lipid droplets; ALDH3B3, plasma membrane). The C-terminal prenylation and two Trp residues are important for the lipid droplet localization of ALDH3B2. 1 ABSTRACT Aldehyde dehydrogenases (ALDHs) catalyze the conversion of toxic aldehydes to non-toxic carboxylic acids. Of the 21 ALDHs in mice, it is the ALDH3 family members (ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, and ALDH3B3) that are responsible for the removal of lipid-derived aldehydes.
    [Show full text]
  • Biological Role and Disease Impact of Copy Number Variation in Complex Disease
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2014 Biological Role and Disease Impact of Copy Number Variation in Complex Disease Joseph Glessner University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, and the Genetics Commons Recommended Citation Glessner, Joseph, "Biological Role and Disease Impact of Copy Number Variation in Complex Disease" (2014). Publicly Accessible Penn Dissertations. 1286. https://repository.upenn.edu/edissertations/1286 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1286 For more information, please contact [email protected]. Biological Role and Disease Impact of Copy Number Variation in Complex Disease Abstract In the human genome, DNA variants give rise to a variety of complex phenotypes. Ranging from single base mutations to copy number variations (CNVs), many of these variants are neutral in selection and disease etiology, making difficult the detection of true common orar r e frequency disease-causing mutations. However, allele frequency comparisons in cases, controls, and families may reveal disease associations. Single nucleotide polymorphism (SNP) arrays and exome sequencing are popular assays for genome-wide variant identification. oT limit bias between samples, uniform testing is crucial, including standardized platform versions and sample processing. Bases occupy single points while copy variants occupy segments.
    [Show full text]
  • Aldehyde Dehydrogenase, Liver Disease and Cancer Wenjun Wang1, Chunguang Wang2, Hongxin Xu1, Yanhang Gao1
    Int. J. Biol. Sci. 2020, Vol. 16 921 Ivyspring International Publisher International Journal of Biological Sciences 2020; 16(6): 921-934. doi: 10.7150/ijbs.42300 Review Aldehyde Dehydrogenase, Liver Disease and Cancer Wenjun Wang1, Chunguang Wang2, Hongxin Xu1, Yanhang Gao1 1. Department of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, 130021, China. 2. Department of Thoracic & Cardiovascular Surgery, Second Clinical College, Jilin University, Changchun, 130041, China. Corresponding author: Yanhang Gao, MD., PhD., Department of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, 130021, China. Email: [email protected]. Tel: +86 15804303019; +86 431 81875121; +86 431 81875106; Fax number: 0431-81875106. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.11.20; Accepted: 2020.01.03; Published: 2020.01.22 Abstract Acetaldehyde dehydrogenase 2 (ALDH2) is the key enzyme responsible for metabolism of the alcohol metabolite acetaldehyde in the liver. In addition to conversion of the acetaldehyde molecule, ALDH is also involved in other cellular functions. Recently, many studies have investigated the involvement of ALDH expression in viral hepatitis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and liver cancer. Notably, ALDH2 expression has been linked with liver cancer risk, as well as pathogenesis and prognosis, and has emerged as a promising therapeutic target. Of note, approximately 8% of the world’s population, and approximately 30-40% of the population in East Asia carry an inactive ALDH2 gene.
    [Show full text]
  • Cells in Diabetic Mice
    ARTICLE Received 12 Jan 2016 | Accepted 18 Jul 2016 | Published 30 Aug 2016 DOI: 10.1038/ncomms12631 OPEN Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic b cells in diabetic mice Ja Young Kim-Muller1,*, Jason Fan1,2,*, Young Jung R. Kim2, Seung-Ah Lee1, Emi Ishida1, William S. Blaner1 & Domenico Accili1 Insulin-producing b cells become dedifferentiated during diabetes progression. An impaired ability to select substrates for oxidative phosphorylation, or metabolic inflexibility, initiates progression from b-cell dysfunction to b-cell dedifferentiation. The identification of pathways involved in dedifferentiation may provide clues to its reversal. Here we isolate and functionally characterize failing b cells from various experimental models of diabetes and report a striking enrichment in the expression of aldehyde dehydrogenase 1 isoform A3 (ALDH þ )asb cells become dedifferentiated. Flow-sorted ALDH þ islet cells demonstrate impaired glucose- induced insulin secretion, are depleted of Foxo1 and MafA, and include a Neurogenin3- positive subset. RNA sequencing analysis demonstrates that ALDH þ cells are characterized by: (i) impaired oxidative phosphorylation and mitochondrial complex I, IV and V; (ii) activated RICTOR; and (iii) progenitor cell markers. We propose that impaired mitochondrial function marks the progression from metabolic inflexibility to dedifferentiation in the natural history of b-cell failure. 1 Naomi Berrie Diabetes Center and Department of Medicine, Columbia University, New York, New York 10032, USA. 2 Department of Genetics and Integrated Program in Cellular, Molecular and Biomedical Studies, Columbia University, New York, New York 10032, USA. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to D.A.
    [Show full text]
  • Phytosphingosine Degradation Pathway Includes Fatty Acid Α
    Phytosphingosine degradation pathway includes PNAS PLUS fatty acid α-oxidation reactions in the endoplasmic reticulum Takuya Kitamuraa, Naoya Sekia, and Akio Kiharaa,1 aLaboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 21, 2017 (received for review January 4, 2017) Although normal fatty acids (FAs) are degraded via β-oxidation, sphingolipids, especially galactosylceramide and its sulfated de- unusual FAs such as 2-hydroxy (2-OH) FAs and 3-methyl-branched rivative sulfatide, contain a 2-OH FA (13, 15, 16). Their 2-OH FAs are degraded via α-oxidation. Phytosphingosine (PHS) is one groups are important for the formation and maintenance of the of the long-chain bases (the sphingolipid components) and exists myelin sheath, which is composed of a multilayered lipid structure, in specific tissues, including the epidermis and small intestine in probably by enhancing lipid–lipid interactions via hydrogen bonds. mammals. In the degradation pathway, PHS is converted to 2-OH The FA 2-hydroxylase FA2H catalyzes conversion of FAs to 2-OH palmitic acid and then to pentadecanoic acid (C15:0-COOH) via FA FAs (12, 17). Reflecting the importance of the 2-OH groups of α-oxidation. However, the detailed reactions and genes involved galactosylceramide and sulfatide in myelin, FA2H mutations cause in the α-oxidation reactions of the PHS degradation pathway have hereditary spastic paraplegia in human (18, 19) and late-onset axon yet to be determined. In the present study, we reveal the entire and myelin sheath degeneration in mice (16, 20).
    [Show full text]
  • Metabolic Network-Based Stratification of Hepatocellular Carcinoma Reveals Three Distinct Tumor Subtypes
    Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes Gholamreza Bidkhoria,b,1, Rui Benfeitasa,1, Martina Klevstigc,d, Cheng Zhanga, Jens Nielsene, Mathias Uhlena, Jan Borenc,d, and Adil Mardinoglua,b,e,2 aScience for Life Laboratory, KTH Royal Institute of Technology, SE-17121 Stockholm, Sweden; bCentre for Host-Microbiome Interactions, Dental Institute, King’s College London, SE1 9RT London, United Kingdom; cDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-41345 Gothenburg, Sweden; dThe Wallenberg Laboratory, Sahlgrenska University Hospital, SE-41345 Gothenburg, Sweden; and eDepartment of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, and approved November 1, 2018 (received for review April 27, 2018) Hepatocellular carcinoma (HCC) is one of the most frequent forms of of markers associated with recurrence and poor prognosis (13–15). liver cancer, and effective treatment methods are limited due to Moreover, genome-scale metabolic models (GEMs), collections tumor heterogeneity. There is a great need for comprehensive of biochemical reactions, and associated enzymes and transporters approaches to stratify HCC patients, gain biological insights into have been successfully used to characterize the metabolism of subtypes, and ultimately identify effective therapeutic targets. We HCC, as well as identify drug targets for HCC patients (11, 16–18). stratified HCC patients and characterized each subtype using tran- For instance, HCC tumors have been stratified based on the uti- scriptomics data, genome-scale metabolic networks and network lization of acetate (11). Analysis of HCC metabolism has also led topology/controllability analysis.
    [Show full text]
  • Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase
    BASIC RESEARCH www.jasn.org Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase † ‡ Yifei Zhong,* Edward Y. Chen, § Ruijie Liu,*¶ Peter Y. Chuang,* Sandeep K. Mallipattu,* ‡ ‡ † | ‡ Christopher M. Tan, § Neil R. Clark, § Yueyi Deng, Paul E. Klotman, Avi Ma’ayan, § and ‡ John Cijiang He* ¶ *Department of Medicine, Mount Sinai School of Medicine, New York, New York; †Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; ‡Department of Pharmacology and Systems Therapeutics and §Systems Biology Center New York, Mount Sinai School of Medicine, New York, New York; |Baylor College of Medicine, Houston, Texas; and ¶Renal Section, James J. Peters Veterans Affairs Medical Center, New York, New York ABSTRACT The Connectivity Map database contains microarray signatures of gene expression derived from approximately 6000 experiments that examined the effects of approximately 1300 single drugs on several human cancer cell lines. We used these data to prioritize pairs of drugs expected to reverse the changes in gene expression observed in the kidneys of a mouse model of HIV-associated nephropathy (Tg26 mice). We predicted that the combination of an angiotensin-converting enzyme (ACE) inhibitor and a histone deacetylase inhibitor would maximally reverse the disease-associated expression of genes in the kidneys of these mice. Testing the combination of these inhibitors in Tg26 mice revealed an additive renoprotective effect, as suggested by reduction of proteinuria, improvement of renal function, and attenuation of kidney injury. Furthermore, we observed the predicted treatment-associated changes in the expression of selected genes and pathway components. In summary, these data suggest that the combination of an ACE inhibitor and a histone deacetylase inhibitor could have therapeutic potential for various kidney diseases.
    [Show full text]
  • Novel Protein Pathways in Development and Progression of Pulmonary Sarcoidosis Maneesh Bhargava1*, K
    www.nature.com/scientificreports OPEN Novel protein pathways in development and progression of pulmonary sarcoidosis Maneesh Bhargava1*, K. J. Viken1, B. Barkes2, T. J. Grifn3, M. Gillespie2, P. D. Jagtap3, R. Sajulga3, E. J. Peterson4, H. E. Dincer1, L. Li2, C. I. Restrepo2, B. P. O’Connor5, T. E. Fingerlin5, D. M. Perlman1 & L. A. Maier2 Pulmonary involvement occurs in up to 95% of sarcoidosis cases. In this pilot study, we examine lung compartment-specifc protein expression to identify pathways linked to development and progression of pulmonary sarcoidosis. We characterized bronchoalveolar lavage (BAL) cells and fuid (BALF) proteins in recently diagnosed sarcoidosis cases. We identifed 4,306 proteins in BAL cells, of which 272 proteins were diferentially expressed in sarcoidosis compared to controls. These proteins map to novel pathways such as integrin-linked kinase and IL-8 signaling and previously implicated pathways in sarcoidosis, including phagosome maturation, clathrin-mediated endocytic signaling and redox balance. In the BALF, the diferentially expressed proteins map to several pathways identifed in the BAL cells. The diferentially expressed BALF proteins also map to aryl hydrocarbon signaling, communication between innate and adaptive immune response, integrin, PTEN and phospholipase C signaling, serotonin and tryptophan metabolism, autophagy, and B cell receptor signaling. Additional pathways that were diferent between progressive and non-progressive sarcoidosis in the BALF included CD28 signaling and PFKFB4 signaling. Our studies demonstrate the power of contemporary proteomics to reveal novel mechanisms operational in sarcoidosis. Application of our workfows in well-phenotyped large cohorts maybe benefcial to identify biomarkers for diagnosis and prognosis and therapeutically tenable molecular mechanisms.
    [Show full text]